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Targeting G-quadruplex DNA with small molecules
Abstract
Despite a recent explosion of interest in G-quadruplex DNA, most fundamental questions regarding the
possible presence and function of these intriguing structures in vivo remain unanswered. Cell-permeable
G-quadruplex specific probes should provide researchers with new tools for studying these alternately
folded DNA structures and their potential involvement in gene expression, chromosome stability, viral
integration, and recombination. In this review, a survey of the binding affinity, specificity, and
biological/pharmacological activities of some well-characterized G-quadruplex ligands is presented
along with the potential importance of G-quadruplex DNA in vivo. 
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Targeting G-Quadruplex DNA with Small 
Molecules
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Abstract: Despite a recent explosion of interest in G-quadruplex DNA, most fundamental questions regarding 
the possible presence and function of these intriguing structures in vivo remain unanswered. Cell-permeable G-
quadruplex specific probes should provide researchers with new tools for studying these alternately folded DNA 
structures and their potential involvement in gene expression, chromosome stability, viral integration, and recom-
bination. In this review, a survey of the binding affinity, specificity, and biological/pharmacological activities of 
some well-characterized G-quadruplex ligands is presented along with the potential importance of G-quadruplex 
DNA in vivo. 
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1. Introduction
First discovered in 1869 by the Swiss bio-
chemist Friedrich Miescher,[1] DNA contin-
ues to amaze and intrigue those devoted to 
its study. The Watson and Crick model for 
B-form duplex DNA,[2] which was based on 
over 80 years of accumulated experimental 
data, dramatically improved our mechanis-
tic understanding of the replication and flow 
of genetic information termed “the central 
dogma of molecular biology” by Francis 
Crick in 1958.[3] Since then, the B-form 
double helix has usually been regarded as 
the biologically relevant structure of DNA, 
however in the context of nucleosome core 
particles and other nucleoprotein complexes 
DNA can adopt a wide variety of conforma-
tions including highly distorted A-, B-, Z-
form double helices.[4]
By necessity, DNA structures are highly 
dynamic and their associated functions are 
potentially diverse. In addition to various 
duplex structures, single-stranded DNAs 
can fold into a wide variety of hairpin, tri-
plex, G-quadruplex, and i-motif structures 
containing non-canonical base pairs.[5] It 
is estimated that approximately 200 such 
structures are deposited in the protein data 
bank as of January 2009. While the casual 
reader might question the biological rel-
evance of single-stranded DNA, it is im-
portant to remember that the metabolically 
active form(s) of DNA (e.g. during replica-
tion, transcription, repair, and recombina-
tion) are single-stranded, allowing kinetic 
access to alternately folded DNA structures 
in vivo. One might even take the extreme 
point of view that the double helix is ac-
tually the inactive form of DNA and that 
single stranded DNAs and their protein 
complexes are more biologically relevant. 
While single-stranded DNA can ex-
hibit structural diversity comparable in 
some ways to that of RNA, DNA’s poten-
tial for forming large complex structures 
is limited by the energetic driving forces 
of duplex formation. Single-stranded DNA 
viral genomes and telomeric DNA circles 
are known exceptions to this rule.[6] The 
thermodynamic and kinetic barriers of du-
plex dissociation, a prerequisite for single-
stranded DNA folding, might be off-set in 
part or in whole by single-stranded DNA 
binding proteins,[7] chaperones,[8,9] small-
molecule binding,[10–12] and/or negative 
supercoiling.[12–16] 
Polypurine–polypyrimidine tracts and 
other repetitive sequences can form non-
duplex and/or higher-order chromatin 
structures possibly related to a wide vari-
ety of biological activities. One family of 
structures originating from guanosine-rich 
tracts is referred to as G-quadruplex (or 
G-tetraplex). These structures, defined as 
containing two or more stacked G-tetrads 
(or G-quartets, Fig. 1), are selectively sta-
bilized by potassium ions at concentrations 
(10–50 mM) well below the 120 mM of 
KCl found in most cells types.[17–19] G-tet-
rads can be assembled in an intramolecular 
(backfolded) fashion or from two-, three-, 
or four- strands in intermolecular struc-
tures capable of adopting a wide variety of 
conformations and folding energies (Fig. 
2).[20–26] Two of the 26 (or more) examples 
of intramolecular G-quadruplex topolo-
gies are shown in Fig 2.[21,27] While G-
quadruplexes can exhibit thermodynamic 
stabilities comparable to those of the cor-
responding duplex structures,[19,28–30] the 
presence and function(s) of these struc-
tures in vivo remains an open question. 
Intermolecular G-quadruplex structures 
have been proposed as intermediates or 
precursors of recombination and/or viral 
integration,[23,31,32] while intramolecular G-
quadruplexes have been implicated in the 
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regulation of gene expression and chromo-
some stability.[33–35] 
No consensus sequence for G-quadru-
plex folding has been experimentally deter-
mined, but approximately 370’000 sequenc-
es with the putative G-quadruplex-forming 
motif (G3+N1-7)4+ (where G = guanosine and 
N = any base) are dispersed throughout the 
human genome.[36,37] These sequences are 
concentrated in promoter regions,[14,38,39] 
introns,[36] 5’ and 3’ UTRs,[40] and at the 
ends of eukaryotic chromosomes.[41,42] 
G-rich sequences having this motif can 
fold into highly stable intramolecular G-
quadruplex structures (T
m
 > 90 oC)[19] that 
usually fold and unfold very slowly at 
room temperature in vitro (kf ~0.001 s–1).[22] 
But much faster rates of folding have been 
observed when G-quadruplex DNA was 
imbedded in a molecular matrix at temper-
atures slightly below the T
m 
(kf ~1.0 s-1).[43] 
Molecular crowding,[44] synthetic and en-
dogenous chaperones,[8–12] and dehydrat-
ing conditions inside the nucleus might 
also accelerate the rates of G-quadruplex 
formation in vivo.[22] 
Due to the self-complementary nature 
of duplex DNA, approximately 370’000 C-
rich motifs (C3+N1-7)4+ (where C = cytosine 
and N = any base) are present in the human 
genome.[36,37] These C-rich sequences can, 
under slightly acidic conditions (pH = 6), 
fold into a type of tetraplex called ‘i-motif’ 
that contains hemi-protonated, intercalated 
C–C+ base pairs (Fig. 1 and Fig. 3). Almost 
nothing is known about the existence or bi-
ological relevance of i-motif DNA in vivo, 
but carboxylated carbon nanotubes have 
recently been shown to bind and stabilize 
i-motif DNA at pH 7 and above.[45] These 
results highlight the possibility that i-mo-
tifs might be formed under physiological 
conditions in vivo through molecular bind-
ing and/or crowding interactions.[30] 
While direct and indirect evidence sup-
ports the presence and biological relevance 
of G-quadruplex structures located in the 
3’ single-stranded overhangs of ciliate te-
lomeres in vivo (presented in Section 4), 
much less information is available regard-
ing the potential relevance of the equilib-
rium depicted in Fig. 3, where certain G–C 
rich DNA sequences can exist as a mixture 
of G-quadruplex/i-motif and canonical 
duplex DNA in vitro.[29,30] Cell-permeable 
ligands that selectively bind to one or more 
of these structures might provide a means 
for probing the existence and/or control-
ling the function(s) associated with these 
structures. These same interactions might 
also provide a new source of therapeutic 
agents and targets.
2. G-Quadruplex DNA as a 
Potential Drug Target 
Many currently used chemotherapeu-
tic agents bind to DNA non-specifically 
(e.g. cisplatin, mitomycin C, chloroethyl 
nitrosoureas, daunomycin, etc.). The de-
velopment of small molecules that specifi-
cally bind to a particular DNA secondary 
structure may improve cancer-specific tar-
geting and decrease the side effects asso-
ciated with chemotherapeutic treatments. 
G-quadruplex DNA structures are highly 
attractive targets given the abundance of 
detailed information available regarding 
their structures,[20,21] thermodynamic sta-
bilities,[22] and potential biological activi-
ties – some of which might be considered 
cancer-specific.[21,31,33–35,46] 
A growing number of groups are tar-
geting G-quadruplex DNA with small 
molecules hoping to inhibit cancer growth 
according to two distinct mechanisms (Fig. 
4). First, the over-expression of oncogenes 
like c-Myc, c-Kit, and KRAS might be in-
hibited by promoter deactivation (Section 
3).[33] The second, more extensively studied 
mechanism, is the inhibition of telomerase, 
a ribonucleoprotein complex that catalyzes 
the 3’ extension of telomeric DNA (Sec-
tions 4 and 5).[20,35,41,42,46,47]
3. Evidence for G-Quadruplex DNA 
as a Modulator of Gene Expression
The expansion of G-containing tri-
nucleotide repeat sequences like (CGG), 
(GAA), and (GGA) is correlated with an 
increased probability of developing inher-
itable diseases such as Friedreich’s ataxia, 
myotonic dystrophy, and Fragile X syn-
drome.[48] These sequences are also highly 
susceptible to S1 nuclease cleavage,[49] 
DNA repair,[50] and can fold into stable 
non-duplex structures in vitro.[48,51,52] In the 
case of a 14-nucleotide repeated sequence 
Fig. 1. Duplex DNA 
contains canonical 
G–C base pairs, 
while i-motif and 
G-quadruplex 
DNAs contain hemi-
protonated C–C+ base 
pairs and G-tetrads, 
respectively.
Fig. 2. G-tetrads can be assembled from a single strand of DNA in an intramolecular (backfolded) 
fashion where two of the 26 (or more) examples of intramolecular G-quadruplex topologies called 
‘chair’ and ‘basket’ are shown.[20–27] Alternatively, two-, three-, or four DNA strands can associate 
in intermolecular G-quadruplex structures. 
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exhibit nuclease hypersensitivity and the 
ability to form G-quadruplex structures in 
vitro.[33,39] Since many of the genes con-
taining potential quadruplex structures are 
overexpressed in cancer tissues, the deac-
tivation of certain promoters by cell-per-
meable G-quadruplex ligands may provide 
a new route to anti-cancer therapies.[33] 
These results highlight the importance of 
developing highly selective G-quadruplex 
ligands that can differentiate between 
closely related G-quadruplex structures, as 
the deactivation of a large number of genes 
will result in non-specific toxicity like in 
the case of TMPyP4.[60,62] It remains an 
open question, however, if G-quadruplex 
structures in or near promoters are ‘nor-
mal’ regulatory elements utilized by tran-
scriptional control machinery in vivo.
4. Evidence for Telomeric 
G-Quadruplex DNA
Pioneering work by Muller and Mc-
Clintock in the 1930s revealed chromo-
somal ends were naturally endowed with 
the ability to prevent fusions with broken 
chromosomes and other telomeric ends.[63] 
Decades of subsequent studies have re-
vealed this telomeric ‘capping’ function 
is related to a wide variety of telomere 
associated proteins,[64,65] attachment to 
the nuclear matrix,[66,67] and higher-order 
chromatin structures.[68–70] It should be 
noted that large differences in telomere 
length,[71] elongation mechanism(s),[6] and 
different telomeric end structures have 
been observed,[6,69] even in closely related 
species and cell types.
The telomeric ends of all known eu-
karyotic chromosomes contain a 3’ single-
stranded overhang.[41,63,72] These overhangs 
contain repetitive G-rich sequences such as 
(G2–3(TG)1–6T)n for Saccharomyces, (TG-
GGGT)
n
 for Tetrahymena, (TTTTGGGG)
n
 
for Stylonychia, (TTTAGGG)
n
 for Arabi-
dopsis, and (TTAGGG)
n
 for vertebrates. 
In the late 1980s G-quadruplex structures 
derived from 3’ telomeric overhangs were 
first reported.[23–26] Since then, many groups 
have speculated about potential relation-
ships between telomeric G-quadruplex 
structures and chromosomal end capping 
activities.[34,35] Interestingly, nearly all re-
ported telomeric sequences can fold into G-
quadruplex structures in vitro.[20–26] While 
it may be an incredible coincidence that di-
verse telomeric sequences can fold into a 
family of closely related structures, there is 
growing evidence that G-quadruplex DNA 
plays a direct role in telomere structure 
and stability in certain organisms.[73–75] 
Direct evidence for the existence of G-
quadruplex DNA at the telomeric ends of 
macronuclei in Stylonychia lemnae has 
been revealed in vivo using G-quadru-
located 363 bp upstream of the human in-
sulin gene, a smaller number of repeats is 
correlated with a higher frequency of type-2 
diabetes mellitus.[53] Mutations capable of 
disrupting the formation of G-quadruplex 
structures in this mini-satellite also dis-
rupted expression of the insulin gene.[54–56] 
These studies were the first to suggest a di-
rect relationship between the formation of 
G-quadruplexes in promoter regions and the 
suppression of gene transcription. Recent-
ly, a trinucleotide repeat (GGA) capable 
of forming G-quadruplex structure(s) was 
shown to have both transcriptional activa-
tion and repressor activities in the context 
of the c-MYB promoter.[52]
Another early example of a putative 
G-quadruplex-containing promoter is the 
non-repetitive nuclease hypersensitive ele-
ment ‘NHEIII1’ located 142 bp upstream of 
the P1 promoter of the c-MYC gene. By us-
ing a combination of DNA point mutations 
and small molecule binding interactions, a 
correlation between G-quadruplex stabili-
zation and the suppression of promoter ac-
tivity was established by the Hurley Lab.[57] 
When 0.1 mM of the cationic porphyrin 
TMPyP4 (presented in detail in Section 
6) was incubated with cells, c-MYC pro-
moter activity decreased by 50% or more. 
When a cell line with the NHEIII1 deleted 
from the c-MYC promoter was used, little 
if any promoter suppression was observed 
after addition of TMPyP4.[57] Since then a 
number of other ligands that exhibit a wide 
range of G-quadruplex affinity and speci-
ficity have been shown to bind promoter-
derived G-quadruplex in vitro and suppress 
the transcription of various genes in cell 
cultures.[47,58–60] Some, but not all, of the 
genes suppressed by TMPyP4 contain a 
putative G-quadruplex forming sequence 
in or near the promoter.[60]
Approximately 30–40% of human pro-
moters contain a putative G-quadruplex 
motif.[39,61] These sequences consistently 
Fig. 3. The equilibrium 
between duplex and 
G-quadruplex/i-motif 
structures can be 
influenced by DNA 
binding proteins,[7] 
small-molecule 
binding,[10–12] negative 
supercoiling,[12–16] 
changes in pH and 
temperature,[29] and 
molecular crowding.[30] 
Fig. 4. Ligand-
mediated stabilization 
of G-quadruplex DNA 
might facilitate the 
regulation of gene 
expression and/or the 
inhibition of telomerase 
activity.
Young AcAdemics in switzerlAnd PArt ii CHIMIA 2009, 63, No. 3 137
plex-specific antibodies.[75] Subsequent 
studies using a combination of RNAi 
and antibodies have provided a direct 
link between telomeric end-binding pro-
teins and the formation of G-quadruplex 
structures in ciliates.[73] Direct evidence 
supporting or refuting the formation of 
G-quadruplex structures in vertebrates 
has so far remained elusive. Indirect evi-
dence for their existence has been inferred 
from competitive binding interactions be-
tween G-quadruplex-selective small mol-
ecules and endogenous binders of the 3’ 
overhang like POT1 and telomerase.[46,74] 
Some studies have also claimed co-local-
ization of G-quadruplex ligands with te-
lomeric ends of metaphase spreads.[76,77] 
Further studies are needed to definitively 
prove (or disprove) the existence and bio-
logical function of telomeric G-quadruplex 
DNA in vertebrates. 
Telomeric end structures have recently 
been resolved at medium resolution using 
electron microscopy and two-dimensional 
gel electrophoresis.[68–70] These studies 
showed that telomeric ends can invade up-
stream duplexes to form a ‘T-loop’ – even in 
protein-free samples.[69] At first glance, the 
T-loop and G-quadruplex telomeric ends 
appear to be mutually exclusive structures, 
but preliminary evidence suggests that a 
G-quadruplex might exist at the junction 
between the single-stranded and double-
stranded regions of the T-loop.[78,79] The 
exact relationship, if any, between T-loop 
and G-quadruplex DNA structures in vivo 
has not yet been determined.[35]
5. G-Quadruplex Ligands as 
Telomerase Inhibitors 
Human telomeres are nucleoprotein 
complexes containing the repeated DNA 
sequence (5’GGGTTA3’)
n
 (n = 100–4,000) 
as a long duplex ending with a short (24–
400 base) single-stranded 3’ overhang.[80,81] 
Telomeric DNA gets shortened by each 
successive round of cellular replication, 
possibly resulting in a molecular clock that 
limits the total number of replicative cycles 
a normal cell can undergo.[82,83] To over-
come this ‘end replication problem’, most 
cancer tissues (~85%) maintain genomic 
stability by telomerase-mediated extension 
of telomeric DNA.[84] Since telomerase is 
over expressed in the majority of malignant 
tumor cells and in relatively few somatic 
cells,[84] it is widely recognized as a po-
tential cancer-specific target.[20,35,41,42,46,47] 
With the knowledge that folded G-qua-
druplex structures are inactive substrates 
for telomerase,[85] many researchers have 
developed small-molecule inhibitors of 
telomerase that stabilize G-quadruplex-
folded structures in the 3’ overhangs of 
telomeric DNA. Indeed, small molecule-
mediated stabilization of the G-quadruplex 
structure(s) can effectively inhibit telom-
erase activity, and when applied to cells, 
G-quadruplex ligands can initiate apopto-
sis or replicative senescence. Many of the 
G-quadruplex ligands used in prior studies, 
like TMPyP4, can bind to many other nu-
cleic acid structures,[86] making alternate 
mechanisms for their reported biological 
effects possible.[60,62,87] 
Targeting telomeric G-quadruplex 
DNA might influence telomere function 
beyond the inhibition of telomerase.[46] 
Chromosomal ends are associated with a 
wide variety of proteins that bind to double-
stranded and/or single-stranded regions of 
the telomeric DNA.[7,35] This nucleopro-
tein or ‘shelterin’ complex maintains the 
structural integrity of telomeres in vivo.[64] 
Small molecules that bind DNA and dis-
place proteins from the shelterin complex 
can cause telomere destabilization, a pos-
sible genotoxicity associated with many 
G-quadruplex ligands.[74] How this type of 
activity might be cancer-specific remains 
an open question.[46] 
6. Some Known G-quadruplex 
Ligands and Their Activities
Detailed structural analyses of G-qua-
druplex-ligand complexes by NMR and 
X-ray crystallography have demonstrated 
at least two types of binding sites for G-
quadruplex ligands.[20,88,89] The most com-
mon is co-facial end-stacking or ‘hemi in-
tercalation’ of the ligand onto one or both 
of the terminal G-tetrads. Other binding 
sites are defined by the surface features of 
the grooves and/or loop regions. In both 
cases, subtle variations of G-quadruplex 
topologies, groove widths, and loop se-
quences can facilitate selective binding 
interactions even between closely related 
G-quadruplex structures.[58,90] It is impor-
tant to note, however, that G-quadruplexes 
are highly dynamic structures and losses in 
DNA conformational entropy upon ligand 
binding might be an important factor in de-
termining specificity. G-quadruplexes that 
exist as a dynamic mixture of conforma-
tions in the unbound state, like the human 
telomeric sequence,[91] should generally 
exhibit lower ligand affinities as compared 
to G-quadruplexes that adopt a single con-
formation.[58,90] 
While a large number of G-quadruplex 
ligands have been reported in the litera-
ture,[41,42,46,89,92–94] the cationic porphyrin 
TMPyP4 (Fig. 5) is the most extensively 
studied to date. TMPyP4 inhibits both 
telomerase (IC50 ≅ 0.7–10 µM)[95,96] and 
Taq DNA polymerase (IC50 ≅ 2 µM).[57] 
Telomerase inhibition by TMPyP4 is rela-
tively insensitive to metal coordination by 
the porphyrin, but is highly dependent on 
the groups at the meso positions.[97] Ex-
tensive substitution of the meso positions 
with groups other than pyridinium failed 
to generate compounds with improved ac-
tivities, but the resulting structure–activity 
relationships demonstrated that base stack-
ing and charge-charge interactions are im-
portant for porphyrin-DNA binding.[97] 
Subsequent X-ray crystallography and 
NMR studies have shown that TMPyP4 
can bind to G-quadruplex DNA at many 
different positions, including the terminal 
G-tetrads,[98] and the loops, grooves, and 
phosphodiester backbone.[99] TMPyP4 
has exhibited some promising antican-
cer activities in vivo,[62,100] but it has very 
poor DNA specificity,[86] causes anaphase 
bridges in sea urchin embryos,[87] and is 
highly toxic in vivo.[62,101] When admin-
istered at 0.1 mM (a dose near its toxic 
limit in cell cultures) TMPyP4 has been 
shown to have a dramatic effect on gene 
expression,[60] and it down-regulates tran-
scription of both c-Myc and the catalytic 
subunit of telomerase.[62] TMPyP4 binds 
to duplex, triplex, G-quadruplex, single-
stranded, and bulk genomic DNA with 
similar affinities (Kd ≅ 200 nM),[86,102] and 
therefore it cannot be considered a struc-
ture-selective ligand. 
The anionic porphyrin N-methyl meso-
porphyrin (NMM), which is commercially 
available as a mixture of four regioisomers, 
has excellent G-quadruplex specificity,[86] 
but relatively poor G-quadruplex affinity 
(Kd ≅ 2−10 µM).[103,104] Changes in the flu-
orescence properties of NMM can be used 
to detect G-quadruplex DNA in vitro.[103] 
Recently, NMM was found to up-regulate 
genes having promoters with a high poten-
tial for G-quadruplex formation, and it also 
suppressed rDNA activity in yeast.[38] The 
binding of rDNA (known to have a high 
potential for G-quadruplex formation) and 
the subsequent suppression of ribosome 
biogenesis is the reported mode of action 
of CX-3543 (quarfloxin), a small molecule 
drug candidate currently in phase II clini-
cal trials.[105]
Telomestatin (SOT-095), a natural 
product isolated from Streptomyces anu-
latus 3533-SV4,[106] is one of the stron-
gest and most specific inhibitors of telom-
erase reported to date (IC50 ≅ 1 µM).[95,96] 
Telomestatin has molecular dimensions 
similar to those of G-tetrad DNA and can 
bind to various G-quadruplexes with mod-
est affinity (Kd ≅ 30 nM).[107] Telomestatin 
exhibits good selectivity for intramolecu-
lar versus intermolecular G-quadruplex 
structures,[108] and it has a 70-fold lower 
affinity for duplex DNA.[108] Telomesta-
tin induces telomere shortening in treated 
cells more rapidly than is expected for a 
single mechanism involving telomerase 
inhibition.[109,110] Recent studies have 
shown that telomere uncapping and the 
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loss of telomeric DNA is related to the 
competition between telomestatin and 
POT1 – a shelterin protein that binds 
to the 3’ single-stranded overhang.[74] 
While it is unknown if this type of activ-
ity might be cancer-selective, telomesta-
tin induces senescence and apoptosis in 
a number of different tumor cell types 
and exhibits less toxicity towards normal 
progenitor cells.[108–111] The administra-
tion of telomestatin to mice containing 
U937 xenografts reduced tumor volumes 
without causing signs of toxicity.[112] 
A total synthesis of telomestatin has re-
cently been reported,[113] but little is known 
about the physicochemical and structural 
features important for its DNA binding 
and pharmacological activities. No SARs 
have been reported for telomestatin, due, 
in part, to the extreme difficulties associ-
ated with the synthesis of its highly con-
strained macrocyclic core.[114] Synthetic 
analogs of telomestatin containing six or 
seven oxazole units have recently been 
prepared and show good G-quadruplex 
affinity and specificity.[115,116] 
7. Concluding Remarks
In recent decades, great strides have 
been made towards the sequence-specific 
targeting of nucleic acids with antisense 
oligonucleotides and polyamide minor 
groove binders.[117,118] These molecules 
have facilitated highly selective gene silenc-
ing, and have found numerous applications 
in basic research and medicine. The phar-
macological potential of these compounds, 
however, is severely limited by the size of 
molecule needed (typically 2,000−5,000 
Da) to achieve sequence specificity in the 
context of the human genome. Compared 
to duplex DNA, G-quadruplex and i-motif 
structures have much more compact struc-
tures that contain well-defined binding 
sites for small molecules. 
Small molecules capable of structure-
selective DNA binding may provide an ex-
citing new avenue for the development of 
anti-cancer agents and molecular probes. 
As novel therapeutics, they have the poten-
tial to extend and improve the lives of those 
suffering from one of the most devastating 
and common causes of premature death. 
A major impediment to the validation of 
G-quadruplex DNA as a new anti-cancer 
drug target is the lack of small molecules 
that bind to G-quadruplex DNA with high 
affinity (Kd < 1 nM) and high specificity (10’000-fold or lower affinity to all other 
nucleic acids). G-quadruplex-specific anti-
bodies generated by in vitro evolution may 
provide key tools for target validation,[75,119] 
while the design and synthesis of new high 
affinity G-quadruplex ligands will provide 
new drug candidates and molecular probes. 
These molecules will provide researchers 
with new tools for studying the potential 
relationships between DNA folding and 
gene expression, chromosome stability, 
viral integration, and recombination. 
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